UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | March 29, 2010 |
Boston Scientific Corporation
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 1-11083 | 04-2695240 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| One Boston Scientific Place, Natick, Massachusetts | 01760-1537 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 508-650-8000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Today we are hosting conference calls with physicians to discuss the recent voluntary removal of our high voltage ICD and CRT-D devices and our new Cardiology, Rhythm and Vascular business. A copy of the script for the conference calls is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. 99.1: Script for March 29, 2010 Physician conference calls.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Boston Scientific Corporation | ||||
| March 29, 2010 | By: | Lawrence J. Knopf | ||
| Name: Lawrence J. Knopf | ||||
| Title: Senior Vice President and Deputy General Counsel | ||||
Exhibit Index
| Exhibit No. | Description | |
99.1 | Script for March 29, 2010 Physician Conference Calls |